Exploratory study of hereditary porphyria diagnosis by porphyrin intermediate metabolite specific spectrum detection using liquid crystal tunable filter (LCTF)
Not Applicable
Recruiting
- Conditions
- hereditary porphyria
- Registration Number
- JPRN-UMIN000036114
- Lead Sponsor
- Tottori University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who conflict with one of the following will not be included in this clinical study. 1) Patients with lead poisoning, liver diseases such as liver cirrhosis / liver cancer, blood diseases such as iron deficiency anemia and sideroblastic anemia, hypermetabolism, endocrine diseases 2) Patients suspected of elemental poisoning such as arsenic and mercury. 3) Patients suspected of intoxication of polyaromatic halide compounds such as dioxin and PCB. 4) Patients taking phenobarbital, cedlumide, griseofulvin, carbamazepine 5) Others who the research researcher deems inappropriate as a patient.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The differential diagnosis of hereditary porphyria (especially, VP, HCP, EPP) by detecting the intrinsic fluorescence spectra of porphyrin intermediate metabolites (Uro III, Copro - III, Pp - IX) in urin/stool samples using LCTF
- Secondary Outcome Measures
Name Time Method 1)Correlation between intrinsic fluorescence spectrum of porphyrin intermediate metabolite and results of HPLC analysis, genetic test(previously obtained). 2)Discrimination of difference in detectability by various clinical samples (urine/stool) 3)Correlation between intrinsic fluorescence spectrum of porphyrin intermediate metabolite and clinical data (gender, age, blood biochemistry data)